For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Tafamidis and Attruby represents a significant breakthrough . These innovative therapies preserve the transthyretin protein, slowing its destructive build-up and reducing the severity of the disease . People are now experiencing i… Read More